Introduction {#s1}
============

Rhinosinusitis (RS) is a major upper airway disease with an overall prevalence of 10.9% in Europe, and has a significant socioeconomic impact \[[@C1]\]. The European position paper on rhinosinusitis and nasal polyps (EPOS) defines RS in adults as an inflammation of the nose and paranasal sinuses, and diagnosis requires the presence of symptomatic and either endoscopic or radiologic criteria. The symptomatic criteria are the presence of at least two of the following symptoms: nasal obstruction, nasal discharge (anterior/posterior nasal drip), reduction/loss of smell and facial pain/pressure, whereof one should be nasal obstruction or nasal discharge \[[@C2]\]. Confirmation of sinus disease using endoscopic or radiological criteria is a requirement, as symptoms are nonspecific and can be manifestations of other diseases, such as upper respiratory tract infection, allergic rhinitis and migraine \[[@C3]\]. The nasal endoscopic criteria are the presence in one or both nasal cavities of nasal polyps, and/or mucopurulent discharge and/or oedema or mucosal obstruction primarily in the middle nasal cavity. The radiological criteria are mucosal changes within the ostiomeatal complex or sinuses on computed tomography examination. Of the two clinical phenotypes of RS, without nasal polyps (RSsNP) is twice as prevalent as with nasal polyps (RSwNP) \[[@C4]\].

The united airway disease (UAD) concept is based on epidemiological and clinical studies that have reported an association of sinonasal diseases, such as allergic rhinitis and RS, with obstructive airway diseases. According to this concept, the upper and lower airways should be considered as a single airway, as disease processes in the lower airway such as inflammation, may affect the upper airway and vice versa \[[@C5], [@C6]\]. Moreover, optimal management of lower airway disease requires that upper airway disease should be assessed and treated appropriately, as exemplified in asthma by the need to assess for and treat coexisting allergic rhinitis and polyps \[[@C7]\].

Chronic obstructive pulmonary disease (COPD) is an inflammatory, progressive lower airway disease with persistent airflow limitation \[[@C8]\]. The main risk factor is exposure to cigarette smoke in developed countries and to biomass smoke in poorly ventilated homes in developing countries \[[@C9]\]. Several epidemiological and clinical studies have suggested an association of COPD with sinonasal symptoms; 40--88% of COPD patients report either current, recurrent or permanent symptoms, such as rhinorrhoea/nasal discharge, nasal obstruction and/or sneezing \[[@C10]--[@C14]\]. However, in a recent review on sinonasal disease and inflammation in COPD, the validity of this association was questioned as the reviewed studies had methodological limitations, such as the absence of a control population, self-reported COPD diagnosis and use of nonstandardised criteria for the diagnosis of RS and COPD \[[@C15]\].

In this study, we investigated the prevalence of RSsNP in COPD and a corresponding control group with respect to age and sex, applying EPOS 2012 and Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for the clinical diagnosis of RS and COPD, respectively. We also investigated the severity of sinonasal symptoms and evaluated the diagnostic accuracy of these symptoms for RS in COPD.

Material and methods {#s2}
====================

Study design and subjects {#s2a}
-------------------------

The study was conducted as an observational cross-sectional study between February 2016 and December 2017 at St. Olavs University Hospital, Trondheim, Norway. COPD patients were recruited from the respiratory outpatient and physical therapy clinics at St. Olavs University Hospital, a private pulmonology practice and several general practitioner offices in Trondheim. Controls were recruited from the general population, via invitation to different workplaces in Trondheim, multiple retirement associations, and posters in various shopping malls and on the hospital\'s social media page. Inclusion criteria were age 40--80 years and no history of sinonasal surgery in both groups, no known lower airway disease in the control group and a post-bronchodilator forced expiratory volume in 1 s (FEV~1~) to forced vital capacity (FVC) ratio of \<0.7 with a negative bronchodilator reversibility test in the COPD group. For both groups, exclusion criteria were any of the following: known underlying systemic diseases that could potentially affect the nose, such as eosinophilic polyangiitis (EGPA) and granulomatous polyangiitis (GPA), cystic fibrosis, primary ciliary dyskinesia/Kartagener syndrome and sarcoidosis, nasal tumours, asthma, current treatment for malignancy, symptoms of common cold within the previous 2 weeks, use of long-term oxygen therapy, a positive bronchodilator reversibility test, presence of nasal polyps on endoscopy, COPD exacerbation within the last 6 weeks. An overview of the study sample is presented in [figure 1](#F1){ref-type="fig"}.

![Overview of the study sample showing excluded subjects in each group with positive reversibility test and nasal polyps.](00015-2020.01){#F1}

All subjects gave oral and written consent for participation in the study. The study was approved by the National Ethical Committee of Norway (reference number 2015/2017), and investigations were performed in accordance with the principles of the Declaration of Helsinki/Hong Kong.

Methods {#s2b}
-------

Subjects were instructed to discontinue the use of systemic antihistamine and corticosteroids at 4 days and nasal decongestants at 12 h prior to the inclusion visit. Nasal corticosteroids were not discontinued. COPD patients were instructed not to take their morning inhaled medication.

Weight and height were recorded for calculation of body mass index (BMI), and spirometry with reversibility test and skin-prick test (SPT) were performed. Subjects completed self-administered questionnaires on smoking habits, symptoms of allergy affecting the airways and sinonasal symptoms. The presence and severity of the latter were evaluated by the sinonasal outcome test-22 (SNOT-22) \[[@C16]\], which is a 22-item questionnaire on nasal and non-nasal symptoms and is a widely recognised and validated tool for RS \[[@C2], [@C16], [@C17]\], and visual analogue scales (VAS), as recommended by EPOS 2012 \[[@C2]\]. An interview and clinical examination with nasal endoscopy were performed by one of three otolaryngologists committed to the study.

### Spirometry with reversibility test {#s2b1}

Pulmonary function tests were performed before and after administration of 0.4 mg salbutamol aerosol by spacer and in accordance with European Respiratory Society (ERS) guidelines for spirometry \[[@C18]\]. Predicted reference values of C[rapo]{.smallcaps} *et al.* \[[@C19]\] were used.

### Skin-prick test {#s2b2}

SPT was performed with an allergen panel consisting of birch, grass and mugwort pollen, cladosporium, house dust mite (*Dermatophagoides pteronyssinus*), and horse, dog and cat epithelia, together with positive and negative controls (Soluprick SQ, ALK-Abello, Horsholm, Denmark). A positive result was defined as a wheal ≥3 mm in diameter 15 min after application \[[@C20]\].

### Allergy status {#s2b3}

Allergic rhinitis was diagnosed based on self-reported symptoms characteristic for rhinoconjunctivitis on exposure to the specific allergen(s) found positive on SPT. The self-reported symptoms must have been present within the last 12 months.

### Smoking status {#s2b4}

Pack-year exposure was calculated, and subjects were categorised into current, former and never-smokers.

### Nasal endoscopy {#s2b5}

Nasal endoscopy was performed with a 2.7 mm, 0° True View II endoscope (Olympus, Japan), and the mucosa in each nasal cavity was evaluated for oedema and mucopurulent discharge. A positive nasal endoscopy was defined as unilateral or bilateral presence of oedema in the middle meatus and/or mucopurulent discharge primarily in the middle nasal cavity \[[@C2]\].

### COPD diagnosis confirmation {#s2b6}

The COPD diagnosis was confirmed by the presence of airflow obstruction, defined as an increase of less than 12% and 200 mL in FEV~1~ after administration of salbutamol by inhalation and a post-bronchodilator FEV~1~/FVC ratio of \<0.7 \[[@C8]\]. Severity of airflow obstruction was graded according to the GOLD 2014 criteria \[[@C8]\].

### Symptomatic criteria of rhinosinusitis {#s2b7}

The symptomatic criteria defined by EPOS were considered present if the respondent had at least two of the four symptoms, of which one was nasal obstruction or nasal discharge. This was determined by dichotomisation of responses to the following items in the SNOT-22 questionnaire: item 4, nasal obstruction; at least one of the following items, nasal discharge (anterior/posterior nasal drip): item 1 (need to blow nose), item 3 (runny nose), item 7 (post-nasal discharge), item 8 (thick nasal discharge); item 5 (loss of taste and smell), reduction/loss of smell; item 12, facial pain/pressure. The response range for each item is 0--5; with 0, no problem and 5, problem as bad as it could be. A response of 0--1 and 2--5 was defined as "symptom not present" and "symptom present", respectively \[[@C21]\].

### Diagnosis of rhinosinusitis without nasal polyps {#s2b8}

The clinical diagnosis of RSsNP was defined as the presence of symptomatic criteria of RS and a positive nasal endoscopy.

### Assessment of symptom severity and diagnostic accuracy of sinonasal symptoms {#s2b9}

Subscales for rhinological and ear/facial symptoms were constructed by summation of responses to item 1--5, 7 and 8 and item 9--12, respectively, in the SNOT-22 questionnaire \[[@C16]\].

The severity of each of the following symptoms was self-assessed on VAS from 0 to 100 mm, with 0 representing "not troublesome" and 100 "worst thinkable troublesome" \[[@C22]\]: nasal obstruction, nasal discharge (anterior/posterior nasal drip), reduced sense of smell, facial pain, sinus pressure, mouth breathing, sneezing and headache. VAS responses to the first three symptoms were summated to obtain a composite VAS for rhinological symptoms and responses to the following two were summated to obtain a composite VAS for facial symptoms.

The diagnostic accuracy of VAS responses \[[@C23]\] for a diagnosis of RSsNP was evaluated by construction of receiver operating characteristics (ROC) curves of the composite VAS for rhinological and facial symptoms for both groups.

Statistical analysis {#s2c}
--------------------

SPSS version 25 (Statistical Packages for the Social Sciences, for Windows, USA) was used for statistical analysis. Continuous variables with a positively skewed distribution were rescaled and log~10~ transformed to obtain a normal distribution prior to analysis. Comparative analyses between groups were performed with t-tests for continuous variables and the Chi-squared statistic, with Fisher\'s exact test when appropriate, for categorical variables. Group comparisons with adjustments for age and sex were also performed using linear regression for continuous variables and logistic regression for categorical variables. The results of the regression analyses did not deviate from the results of the Chi-squared and t-tests, thus results are presented as mean±[sd]{.smallcaps} and frequencies and percentages, respectively. Area under the ROC curve with 95% confidence intervals were computed for composite VAS for rhinological and facial symptoms to compare the diagnostic accuracy, and a value \>0.8 has a good diagnostic accuracy \[[@C24]\]. Independent group area difference under the ROC curve was used for tests of statistical significance between COPD and control groups. The level of significance was set at the standard two-sided level of 5%.

Results {#s3}
=======

Subject characteristics {#s3a}
-----------------------

In the studied sample, the mean age of 90 subjects with COPD and 93 control subjects were 66.2 and 63.7 years, respectively. Sex and BMI were evenly distributed in the two groups. The prevalence of allergic rhinitis was almost three times higher in control subjects than in COPD subjects ([table 1](#TB1){ref-type="table"}). Airflow limitation was moderate (GOLD2) in 44% and severe (GOLD3) in 37% of COPD subjects ([table 2](#TB2){ref-type="table"}).

###### 

Subject characteristics

                               **COPD**    **Control**   **p-value**
  --------------------------- ----------- ------------- -------------
  **Subjects n**                  90           93       
   Males                       49 (54.4)    51 (54.8)       0.96
  **Age years**                66.2±8.7     63.7±8.7        0.051
  **Smoking status**                                    
   Current                     17 (18.9)     7 (7.5)       \<0.001
   Former                      68 (75.6)    47 (50.5)   
   Never                        5 (5.6)     39 (41.9)   
   Pack-years^\#^              28.6±20.9    6.6±10.8       \<0.001
  **BMI kg·m^2^**              27.0±5.4     27.3±4.7         0.7
  **Allergic rhinitis**         5 (5.6)     14 (15.1)       0.035
  **Nasal corticosteroids**     4 (4.4)      4 (4.3)         1.0
  **Pulmonary function^¶^**                             
   FEV~1~ L                     1.6±0.7      3.0±0.9       \<0.001
   FEV~1~ % pred               53.1±18.7    94.6±12.2      \<0.001
   FVC L                        3.0±1.0      3.7±1.0       \<0.001
   FVC % pred                  75.8±18.0    93.8±13.0      \<0.001
   FEV~1~/FVC                  0.53±0.12    0.78±0.05      \<0.001

Data presented as n (%) or mean±[sd,]{.smallcaps} unless otherwise stated. The p-values refer to data comparison between COPD and controls. COPD: chronic obstructive pulmonary disease; BMI: body mass index; FEV~1~: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity. ^\#^: Missing data in four controls and three COPD; ^¶^: pre-bronchodilator values in two controls and one COPD. Otherwise, pulmonary function parameters are based on post-bronchodilator measurements.

###### 

Grade of airflow limitation in COPD subjects

                              **Post-bronchodilator FEV~1~, mean±[sd]{.smallcaps}**            
  ------------ ------------- ------------------------------------------------------- --------- ----------
  **GOLD 1**   Mild                                  7 (7.8)                          2.7±0.8   85.7±4.2
  **GOLD 2**   Moderate                             40 (44.4)                         1.9±0.6   65.5±8.1
  **GOLD 3**   Severe                               33 (36.7)                         1.2±0.3   40.0±5.3
  **GOLD 4**   Very severe                          10 (11.1)                         0.7±0.2   24.4±3.6

GOLD: Global Initiative for Chronic Obstructive Lung Disease; FEV~1~: forced expiratory volume in 1 s; % pred: % predicted.

Symptoms and diagnostic criteria of RS {#s3b}
--------------------------------------

The prevalence of three of the four symptoms of RS were significantly greater in the COPD group than in the control group ([figure 2a](#F2){ref-type="fig"}). In both groups, nasal discharge was the most prevalent, followed in decreasing order by nasal obstruction, impaired taste and smell and facial pain/pressure.

![a) Prevalence of symptoms of rhinosinusitis (European position paper on rhinosinusitis and nasal polyps (EPOS) criteria). Data derived from sinonasal outcome test (SNOT)-22. b) Rhinological and ear/facial SNOT subscales. Data are presented as mean±[sd]{.smallcaps}.](00015-2020.02){#F2}

The prevalence of symptomatic criteria for RS in COPD subjects was twice the prevalence in controls, (57 (63%) *versus* 28 (30%), p\<0.001) and the endoscopic criteria was 1.5-fold more prevalent in COPD than in controls (63 (70%) *versus* 42 (45%), p=0.003) ([figure 3](#F3){ref-type="fig"}).

![Prevalence of symptomatic and endoscopic criteria and rhinosinusitis without nasal polyps (RSsNP) in chronic obstructive pulmonary disease (COPD) and control groups.](00015-2020.03){#F3}

### Prevalence of RSsNP {#s3b1}

The prevalence of RSsNP in the COPD group was 51% (n=46) and over threefold higher than in the control group (n=15, p\<0.001) ([figure 3](#F3){ref-type="fig"}). When subjects with allergic rhinitis were excluded, the diagnosis of RSsNP remained significantly greater in the COPD group than in controls (41 (48%) *versus* 12 (15%), p\<0.001).

RSsNP was diagnosed in 47% (32 of 68) former and 65% (11 of 17) current smokers in the COPD group and in 19% (9 of 47) former and 29% (2 of 7) current smokers in the control group (p=0.35).

In the COPD group, RSsNP was diagnosed in 27 (59%) males and 19 (41%) females (p=0.41) and in 2 (29%), 18 (45%), 19 (58%) and 7 (70%) subjects with mild, moderate, severe and very severe airflow limitation (GOLD 1--4), respectively.

### Severity of sinonasal symptoms {#s3b2}

The total SNOT-22 score was significantly higher in the COPD group than in controls (29.8±18.8 *versus* 16.6±15.5, p\<0.001). SNOT subscale scores of rhinological and ear/facial symptoms were significantly higher in the COPD group than in the control group ([figure 2b](#F2){ref-type="fig"}).

VAS for nasal obstruction, reduced sense of smell, mouth breathing, and sneezing were significantly greater in the COPD group than in the control group ([table 3](#TB3){ref-type="table"}), while nasal discharge, facial pain and sinus pressure were not. The composite VAS score was significantly higher for rhinological symptoms in the COPD group than in the control group and was not significantly different for facial symptoms between the two groups ([table 3](#TB3){ref-type="table"}).

###### 

Visual analogue scales (VAS) (mm) for sinonasal symptoms

  **Sinonasal symptoms**                              **COPD (n=90)**   **Control (n=93)**   **p-value**
  -------------------------------------------------- ----------------- -------------------- -------------
  **Nasal obstruction^a^**                               23.4±25.9          14.1±21.2           0.007
  **Nasal discharge (anterior/posterior drip)^b^**       20.5±26.3          13.4±21.1           0.12
  **Reduced sense of smell^c^**                          16.0±25.3           6.9±5.4            0.014
  **Facial pain^d^**                                     6.4±14.2            4.7±12.4           0.65
  **Sinus pressure^e^**                                  9.5±20.4            6.9±16.4           0.42
  **Mouth breathing**                                    24.9±28.1          11.9±20.1           0.001
  **Sneezing**                                           17.8±20.8          10.8±20.1           0.002
  **Headache**                                           14.6±22.1          10.9±19.6           0.25
  **Composite rhinological VAS (a+b+c)**                 59.9±61.9          34.4±51.4           0.001
  **Composite facial VAS (d+e)**                         15.9±37.7          11.5±27.0            0.4

Data are presented as mean±[sd,]{.smallcaps} unless otherwise stated.

### Diagnostic accuracy of sinonasal symptoms for RSsNP {#s3b3}

The area under the curve (95% CI) of the ROC curve for the composite rhinological VAS was not significantly different in the COPD and control groups (0.82 (0.73--0.90) *versus* 0.85 (0.76--0.95), p=0.56). The cut-off composite rhinological VAS score was 56 and 36.5 for COPD and controls, respectively. The ROC curve values for the composite facial VAS were 0.63 (0.51--0.74) *versus* 0.82 (0.68--0.95), p=0.03 ([figure 4](#F4){ref-type="fig"}).

![Receiver operating characteristic curves and diagnostic accuracy of (a) composite rhinological visual analogue scale (VAS) and (b) composite facial VAS in chronic obstructive pulmonary disease (COPD) and controls for a diagnosis of rhinosinusitis without nasal polyps (RSsNP) using European position paper on rhinosinusitis and nasal polyps (EPOS) criteria. AUC: area under the curve; CI: confidence interval.](00015-2020.04){#F4}

Discussion {#s4}
==========

In this study, we found that COPD is associated with RS and sinonasal symptoms have significantly greater severity in COPD subjects than in controls. This association is supported by a clinical diagnosis of RSsNP in 51% and the presence of symptomatic criteria of RS in over 60% of COPD subjects ([figure 3](#F3){ref-type="fig"}). Moreover, RSsNP is threefold and symptomatic and endoscopic criteria of RS are 1.5--2-fold more prevalent in the COPD group than in the control group. The greater severity of sinonasal symptoms in COPD is evident when these symptoms are assessed by SNOT-22 subscales for rhinological and ear/facial symptoms ([figure 2b](#F2){ref-type="fig"}), VAS for individual symptoms and composite VAS for rhinological symptoms ([table 3](#TB3){ref-type="table"}). The latter has a superior diagnostic accuracy for RS than the composite VAS for facial symptoms ([figure 4](#F4){ref-type="fig"}).

The prevalence of nasal discharge, nasal obstruction and impaired taste and smell varied from 72 to 37% in COPD subjects in this study and was significantly greater than in controls ([figure 2a](#F2){ref-type="fig"}). Previous studies have found that sinonasal symptoms are frequently reported by COPD patients \[[@C10]--[@C14], [@C25], [@C26]\]. However, those studies had limitations, such as the lack of a control group \[[@C11], [@C13], [@C14], [@C27]\] and spirometric confirmation of COPD diagnosis \[[@C10], [@C14], [@C26], [@C27]\], which have been addressed in our study. Moreover, we found that almost two out of three subjects with COPD fulfilled the EPOS symptomatic criteria for RS. This prevalence is threefold higher than that reported in a Brazilian study by C[aminha]{.smallcaps} *et al.* \[[@C21]\]. The difference in prevalence rates is consistent with the large variability in the overall prevalence rates of 7--27% reported across 12 countries in the 2011 pan-European prevalence study \[[@C1]\]. Our prevalence of 63% is slightly greater than that of 53% reported by K[elemence]{.smallcaps} *et al.* \[[@C14]\]. However, that study is not fully eligible for comparison, as the definition of symptomatic RS included EPOS criteria as well as headache, ear pain, halitosis and fatigue.

To our knowledge, this is the first study where EPOS endoscopic criteria were used for a diagnosis of RSsNP in COPD and control subjects. Our finding of RSsNP in every other subject with COPD is in accordance with the prevalence of 49% reported by Y[ang]{.smallcaps} *et al.* \[[@C27]\]. However, there are differences between the two studies. In Yang\'s study, there was no control group; headache was included in the symptomatic criteria and radiologic criteria were used to diagnose RS. Nasal endoscopy is the only modality that discriminates RSsNP from RSwNP. Moreover, in our study, we also evaluated for allergic rhinitis at the time of inclusion, as this entity affects 10--20% of the adult population \[[@C28]\] and can mimic symptoms of RS. Although allergic rhinitis was almost threefold more frequent in the control group, the relative prevalence of RSsNP in the COPD group was unchanged, which suggests that the high prevalence of RSsNP is not due to undiagnosed allergic rhinitis.

In addition to being more prevalent ([figure 2a](#F2){ref-type="fig"}), the severity of RS symptoms was greater in COPD than in controls as demonstrated by data obtained from the SNOT-22 and VAS. The SNOT subscales showed that COPD subjects were significantly more troubled than controls by rhinological and ear/facial symptoms ([figure 2b](#F2){ref-type="fig"}). This suggests that altered nasal conditions secondarily may lead to increased mouth breathing and thus inadequate protection and homeostasis of the lower airways in COPD which is in line with the UAD concept. Future studies should investigate whether RS symptoms have an impact on quality of life in COPD.

Further, the prevalence of RSsNP was 47% and 19% in COPD and controls former smokers respectively and increased by almost 1.5 in current smokers in both groups, which may indicate that cigarette smoke has a negative effect in the upper airway. Cigarette smoke has been proposed to have pathophysiological effects on the sinonasal mucosa that can account for increased frequency of upper airway symptoms and impairment of olfaction \[[@C29], [@C30]\].

It would be clinically beneficial to have a simple instrument to screen COPD patients for RS. This is desirable as both patients and their physicians underrecognise sinonasal symptoms \[[@C6], [@C31]\], and RS is independently associated with treatment failure in COPD exacerbations \[[@C32]\]. In the present study, three rhinological VAS items were summated, and the resulting composite VAS score of 56 or higher had the best diagnostic accuracy for RSsNP in COPD patients, with a sensitivity and specificity of 63% and 80%, respectively. The composite VAS may have a potential for selecting COPD patients for further assessment by an otolaryngologist. However, the cut-off value for a specificity of 80% was higher in COPD than in control subjects, which may be due to differences in symptom burden in the two groups. The cut-off value may variate depending on sample characteristics and care settings \[[@C33]\]. As such, it will be prudent to validate the relationship between the composite rhinological VAS score and the diagnosis of RSsNP in larger cohorts of COPD patients, preferably in relation to the severity of airflow limitation, and of control subjects in primary and specialist care settings.

The strengths of this study are the relatively large sample size with almost equal sex representation, inclusion of COPD patients across the spectrum of disease severity, inclusion of a control group similar in age, number and from the same population area, as well as the use of globally accepted diagnostic criteria for RS and COPD. Spirometry with reversibility testing allowed us to eliminate asthma on COPD overlap and allergy testing permitted discrimination of RS symptoms from allergic rhinitis. There is a possibility of a recruitment bias of subjects with sinonasal symptoms in the control group, as the protocol included clinical examination by an otolaryngologist. This limitation may account for the higher mean subscale score of the SNOT rhinological symptoms in our control group, compared to the control population in a study by E[rskine]{.smallcaps} *et al.* \[[@C17]\]. Conversely, this limitation could add strength to our study as the results would be more significant if the bias was absent. Another limitation was our inability to evaluate the impact of RS on exacerbations of COPD, due to the lack of access to exacerbation data.

Conclusion {#s5}
==========

RSsNP is present in 51% of our COPD patients and is threefold more prevalent in the COPD group than in controls. These results suggest that COPD is associated with RS.
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